Drug Profile
CRB 604
Latest Information Update: 05 Sep 2007
Price :
$50
*
At a glance
- Originator Korea Institute of Science and Technology
- Developer Chong Kun Dang
- Class Antibacterials; Cephalosporins
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 12 Jul 2000 No-Development-Reported for Bacterial infections in South Korea (Unknown route)
- 17 May 1995 New profile
- 17 May 1995 Preclinical development for Bacterial infections in South Korea (Unknown route)